The Shareholders Foundation announced that an investor, who purchased NASDAQ:TGTX shares, filed a lawsuit over alleged Securities Laws violations by TG Therapeutics Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of TG Therapeutics Inc (NASDAQ:TGTX) have certain options and for certain investors are short and strict deadlines running. Deadline: March 7, 2017. NASDAQ:TGTX investors should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
According to the complaint the plaintiff alleges on behalf of certain purchasers of TG Therapeutics Inc (NASDAQ:TGTX) common shares that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between September 15, 2014 and October 12, 2016 TG Therapeutics Inc alegedly misrepresented and/or omitted material information concerning its GENUINE Phase III clinical trial for its proprietary combination of drug therapies TG-1101 and TGR-1202.
The Phase III trial consisted of two parts, Part I evaluating the effect of the addition of TG-1101 to ibrutinib on overall response rate (ORR) in approximately 200 patients, and Part II evaluating the effect of the addition of TG-1101 to ibrutinib on progression-free survival (PFS) in all study patients.
On October 13, 2016, TG Therapeutics Inc that it had filed with the FDA an amended protocol for its leukemia drug combination, GENUINE Phase 3 Trial. In the amendments, the Company eliminated part II of the GENUINE study and reduced the number of randomized patients from 200 to approximately 120. The Company no longer benefits from of its previously negotiated Special Protocol Assessment with the FDA. Shares of TG Therapeutics Inc (NASDAQ:TGTX) declined to as low as $6.54 per share on October 14, 2016.
Those who purchased NASDAQ:TGTX shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego